Financials
Financial year 2025
BIOMDRIN from Schilde, company number BE1004523585, closed financial year 2025 with a result of € 2,799 after tax. For that financial year BIOMDRIN recorded a gross margin of € 4,129 and equity of € 22,328. Compared with financial year 2024, the result moved from € 14,529 to € 2,799. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.
€ 22,328
▲ 14% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2,799
▼ 81% vs 2024
Profit after tax over the fiscal year.
€ 11,685
▲ € 10,573 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 17,328.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 15,214
▲ 182% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 725
▼ 84% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 19,713 | € 4,129 | ▼ 79% |
| Profit after taxes | € 14,529 | € 2,799 | ▼ 81% |
| Equity | € 19,529 | € 22,328 | ▲ 14% |
| Total debts | € 9,972 | € 15,939 | ▲ 60% |
| Cash | € 1,113 | € 11,685 | ▲ € 10,573 |
| Retained profit | € 14,529 | € 17,328 | ▲ 19% |
| Balance sheet total | € 29,501 | € 38,268 | ▲ 30% |
Key figures of BIOMDRIN, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BIOMDRIN?
What happened at BIOMDRIN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 2,799 (▼ 81% vs 2024). Source: NBB ↗
- Josue Jimenez Vazquez became a director. NBB
- Anthony Van Campen became a director. NBB
- Patrick van der Linden became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 14,529 profit in 2024 to € 2,799 profit in 2025.
Paid € 4,357 in corporate taxes since 2024.
Best year ever: 2024, with € 14,529 profit.
A new publication or filing at BIOMDRIN? We notify you, reason included.
Follow BIOMDRINDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind BIOMDRIN are Josue Jimenez Vazquez, Anthony Van Campen and Patrick van der Linden. Anthony Van Campen is also behind LIFESPAN.
Directors
According to the 2025 annual accounts
Josue Jimenez Vazquez
Director
since 2024
since 2024
Patrick van der Linden
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Den Aard 18 box A
2970 Schilde
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1004.523.585
- VAT number
- BE 1004.523.585
- Registered office
- Den Aard 18 bus A, 2970 Schilde
- Names & denominations
- BIOMDRIN
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 January 2024
- Peppol
- Active · Active since 7 Oct 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied